tiprankstipranks
Trending News
More News >
Pfizer (PFE)
NYSE:PFE
US Market

Pfizer (PFE) Earnings Dates, Call Summary & Reports

Compare
33,830 Followers

Earnings Data

Report Date
Aug 05, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
0.57
Last Year’s EPS
0.6
Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings

Earnings Call Summary

Earnings Call Date:Apr 29, 2025
|
% Change Since: 2.21%
|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Neutral
Pfizer's earnings call highlighted a strong R&D pipeline and strategic focus on growth areas such as oncology and cardiometabolic segments, alongside significant growth in key products. However, the company also faced challenges, including a decline in overall revenue and potential impacts from global trade uncertainties and competition. Despite these challenges, Pfizer demonstrated strong operational efficiency and cost management, positioning itself for future growth.
Company Guidance
During Pfizer Inc.'s First Quarter 2025 Earnings Conference Call, the company reaffirmed its guidance for the fiscal year 2025, projecting total company revenues to be in the range of $61 to $64 billion and adjusted diluted earnings per share between $2.80 and $3.00. The call highlighted Pfizer's focus on improving R&D productivity, with anticipated milestones including at least four regulatory decisions and up to nine phase three readouts. The company reported first-quarter revenues of $13.7 billion, a 6% operational decline, primarily due to lower PAXLOVID revenues and changes in the IRA Medicare Part D redesign. However, Pfizer recorded strong growth in several key products, with adjusted diluted earnings per share reaching $0.92, attributed to robust gross margin and cost management. The company also emphasized its strategic priorities of enhancing shareholder value, maintaining a strong dividend policy, and pursuing disciplined capital allocation with reinvestments in R&D and potential external opportunities, despite the macroeconomic uncertainties such as potential tariffs and the complex global trade environment.
Strong R&D Pipeline and Strategic Focus
Pfizer emphasized strengthening its R&D organization with a focus on cardiometabolic and oncology segments. Anticipated multiple key milestones include at least four regulatory decisions and up to nine phase three readouts in 2025.
Significant Revenue Growth in Key Products
The Vintechl family of products saw robust growth, and the oncology portfolio, specifically Tatsit, grew by 25% in revenue. The company also reported a 40% revenue growth for Northrop America.
Operational Efficiency and Cost Management
Pfizer reported a 12% operational decline in total adjusted operating expenses and is on track to deliver $4.5 billion in cumulative net cost savings by the end of 2025.
Strong Performance in US and International Markets
Pfizer reported strong contributions across its product portfolio and noted significant market growth in international regions, particularly with products like Nortech, Tatsit, and Blurbbrand.

Pfizer (PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

PFE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 05, 2025
2025 (Q2)
0.57 / -
0.6
Apr 29, 2025
2025 (Q1)
0.67 / 0.92
0.8212.20% (+0.10)
Feb 04, 2025
2024 (Q4)
0.47 / 0.63
0.1530.00% (+0.53)
Oct 29, 2024
2024 (Q3)
0.61 / 1.06
-0.17723.53% (+1.23)
Jul 30, 2024
2024 (Q2)
0.46 / 0.60
0.67-10.45% (-0.07)
May 01, 2024
2024 (Q1)
0.52 / 0.82
1.23-33.33% (-0.41)
Jan 30, 2024
2023 (Q4)
-0.16 / 0.10
1.14-91.23% (-1.04)
Oct 31, 2023
2023 (Q3)
-0.08 / -0.17
1.78-109.55% (-1.95)
Aug 01, 2023
2023 (Q2)
0.57 / 0.67
2.04-67.16% (-1.37)
May 02, 2023
2023 (Q1)
0.98 / 1.23
1.62-24.07% (-0.39)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PFE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 29, 2025
$22.62$23.34+3.18%
Feb 04, 2025
$25.71$25.38-1.28%
Oct 29, 2024
$27.43$27.05-1.39%
Jul 30, 2024
$29.20$29.84+2.19%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pfizer (PFE) report earnings?
Pfizer (PFE) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
    What is Pfizer (PFE) earnings time?
    Pfizer (PFE) earnings time is at Aug 05, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PFE EPS forecast?
          PFE EPS forecast for the fiscal quarter 2025 (Q2) is 0.57.

            Pfizer (PFE) Earnings News

            PFE Earnings: Pfizer Stock Jumps on Q4 Beats
            Premium
            Market News
            PFE Earnings: Pfizer Stock Jumps on Q4 Beats
            4M ago
            BNTX Earnings: BioNTech Reports Better-than-Expected Q3 Earnings, Lowers Revenue Outlook
            Premium
            Market News
            BNTX Earnings: BioNTech Reports Better-than-Expected Q3 Earnings, Lowers Revenue Outlook
            7M ago
            PFE Earnings: Pfizer Gains on Strong Q3 Results, Raises Outlook
            Premium
            Market News
            PFE Earnings: Pfizer Gains on Strong Q3 Results, Raises Outlook
            7M ago
            PFE Earnings: Pfizer Blows Past Estimates in Q2
            Premium
            Market News
            PFE Earnings: Pfizer Blows Past Estimates in Q2
            10M ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis